[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ahmad Shariftabrizi\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100561122","early-phase-1-breast-cancer-psma-pet-100561122",false,"NCT06586047","Breast Cancer PSMA PET","Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET\u002FCT","Inclusion Criteria:\n\n* Female \\>= 18 years of age\n* Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.\n* Patient should have FDG positive metastatic lesions on the initial PET\u002FCT scan performed in this study to be further included.\n\nExclusion Criteria:\n\n* Patients with known active other malignancy.\n* Unable to tolerate PET\u002FCT procedure.\n* Pregnant or breastfeeding.\n* Patients with any medical condition that might compromise the safety of subject during PET acquisitions.","FEMALE","18 Years","90 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET\u002FCT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.",[27],"Triple Negative Breast Cancer",[29],"Breast cancer, PSMA expression, PET imaging","RECRUITING","2026-08-05",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":34},"2024-08-29",{"date":38,"type":21},"2027-09-01",{"name":40,"class":41},"Ahmad Shariftabrizi","OTHER",""]